Radiopharm Theranostics (RAD) News Today → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free RAD Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRadiopharm Theranostics Ltd Ordinary Sharesmorningstar.com - March 16 at 12:21 AMRadiopharmaceutical market expected to reach ~$14B by 2032msn.com - February 25 at 2:12 PMRadiopharm Theranostics Limited (RDPTF)uk.finance.yahoo.com - February 13 at 1:18 PMRadiopharm Theranostics' novel monoclonal antibody shows promise in cancer treatmentau.investing.com - February 5 at 3:29 AMRadiopharm Theranostics completes entitlement offer shortfall for $1.7 millionau.investing.com - January 26 at 12:55 AMRadiopharm Theranostics Ltd Ordinary Shares RADmorningstar.com - January 20 at 6:30 PMRadiopharm Theranostics to open second Australian site for lung cancer trialau.investing.com - December 27 at 12:14 AMRadiopharm Theranostics launching Phase 1 lung cancer trials in Januaryau.investing.com - December 22 at 2:51 PMRadiopharm Theranostics' $4.85 million R&D refund will support development of radiopharmaceutical productsau.investing.com - November 20 at 10:46 PMRadiopharm Theranostics launches $10 million entitlement offer to fund clinical trialsproactiveinvestors.com.au - October 30 at 10:27 PMRadiopharm Theranostics receives FDA greenlight to start Phase 1 imaging trial of RAD 301proactiveinvestors.com.au - October 16 at 10:20 PMRAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancerfinance.yahoo.com - October 9 at 7:41 AMRadiopharm Theranostics secures approval for Phase 1 PDL1-nanobody non-small cell lung cancer studyproactiveinvestors.com.au - October 9 at 1:01 AMRadiopharm Theranostics Full Year 2023 Earnings: AU$0.11 loss per share (vs AU$0.17 loss in FY 2022)finance.yahoo.com - September 1 at 4:37 PMRadiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancerfinance.yahoo.com - August 24 at 8:41 AMRadiopharm Theranostics expands TerThera supply agreement for prostate cancer treatment trialproactiveinvestors.com - August 24 at 3:40 AMRadiopharm Theranostics appoints experienced radiopharmaceutical developer as VP Medical and Corporate Affairsproactiveinvestors.com.au - July 24 at 4:43 AMTheradiag Reports Revenue of €6.7 Million for the First Half of 2023, up 6.8%finance.yahoo.com - July 23 at 8:14 PMIs Radiopharm Theranostics (ASX:RAD) In A Good Position To Invest In Growth?finance.yahoo.com - July 19 at 6:29 AMRadiopharmaceuticals Global Market is Projected to Reach $12.6 Billion by 2030: Innovative Radiopharmaceuticals to Boost Cardiac Applicationsmarketwatch.com - June 23 at 9:16 AMDiamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023finance.yahoo.com - June 9 at 8:54 AMRadiopharm Theranostics maintains A$0.70 valuation from Diamond Equity Researchproactiveinvestors.com.au - June 6 at 11:19 PMRadiopharm welcomes positive guidance from FDA to advance Pivalateproactiveinvestors.com.au - May 31 at 12:20 AMRadiopharm Theranostics receives positive guidance from FDA to file IND application for RAD 101proactiveinvestors.com.au - May 29 at 3:15 AMRadiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancerfinance.yahoo.com - May 9 at 10:25 AMASX Health Stocks: The US FDA will pay a visit to Cyclopharm’s facility in NSWmsn.com - May 9 at 12:24 AMRadiopharm Theranostics garners FDA orphan drug designation for pancreatic cancer therapy Trivehexinproactiveinvestors.com.au - May 9 at 12:24 AMRadiopharm Theranostics initiated by Jones Research with buy rating and A$0.75 price targetproactiveinvestors.com.au - April 19 at 10:26 AMRadiopharm Theranostics secures pivotal isotope for cancer-targeting peptideproactiveinvestors.com.au - April 18 at 2:01 AMRadiopharm Theranostics enters supply agreement with TerThera for isotope used in cancer therapyproactiveinvestors.com.au - April 17 at 10:55 AMRadiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotopefinance.yahoo.com - April 17 at 10:55 AMRadiopharmaceutical Theranostics Market Worth $3.44 Billion, Globally, by 2028 at 11.3% CAGR | The Insight Partnersbenzinga.com - March 29 at 1:45 PMRadiopharm Theranostics Invited to Participate in Jefferies Radiopharma Innovation Summitfinance.yahoo.com - March 28 at 10:06 AMRadiopharm Theranostics forms multi-year strategic research partnership with GenesisCare to develop radiopharmaceuticalsproactiveinvestors.com.au - March 27 at 12:36 AMRadiopharm Theranostics taps nuclear medicine physician Dr Ken Herrmann for its scientific advisory boardproactiveinvestors.com.au - March 2 at 11:34 PMRadiopharm Theranostics Ltd.barrons.com - February 25 at 7:43 PMRadiopharm Theranostics Initiates Process for Nasdaq Listingfinance.yahoo.com - February 14 at 8:44 AMRadiopharm Theranostics initiates Nasdaq listing process; trading likely to begin in Marchproactiveinvestors.com - February 13 at 8:03 PMRadiopharm Theranostics talks clinical development and Nasdaq listingproactiveinvestors.com.au - February 13 at 8:03 PMRadiopharm Theranostics valuation reiterated by Diamond Equity Research following progress in clinical trialau.investing.com - February 6 at 11:10 AMRadiopharm Theranostics Limitedafr.com - January 24 at 7:29 PMRadiopharm Theranostics appoints senior VP of Chemistry, Manufacturing and Controlsproactiveinvestors.com - January 10 at 10:57 PMRadiopharm Theranostics Limited (RAD.AX)au.finance.yahoo.com - January 4 at 9:09 AMRadiopharm Theranostics Ltdreuters.com - December 17 at 10:03 PMRadiopharm Theranostics’ RAD201 asset, targeting breast cancer tumours, gets positive write-up in prestigious journalproactiveinvestors.com.au - December 12 at 11:06 PMRadiopharm Theranostics earns nearly six-fold price upside on recent developments, successful execution: Diamond Equity Researchproactiveinvestors.com.au - December 7 at 3:35 PMRadiopharm Theranostics welcomes additional data from Phase 2a brain metastases trialproactiveinvestors.com.au - November 22 at 9:53 PMRadiopharm Theranostics reaches agreement with ANSTO for supply of key isotope lutetium-177proactiveinvestors.com.au - November 21 at 9:24 PMRadiopharm Theranostics Signs Agreement With NorthStar Medical Radioisotopes for the Supply of Non-Carrier Added (n.c.a.) Actinium-225finance.yahoo.com - October 26 at 12:23 PMRadiopharm Theranostics secures second supply of Actinium-225 from NorthStar Medical Radioisotopesproactiveinvestors.com.au - October 25 at 9:20 PM Get Radiopharm Theranostics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Warning: this could blow your mind (Ad)Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting… Watch the presentation here RAD Media Mentions By Week RAD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAD News Sentiment▼0.000.60▲Average Medical News Sentiment RAD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAD Articles This Week▼00▲RAD Articles Average Week Get Radiopharm Theranostics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Artelo Biosciences News Today Ascletis Pharma News Today Avacta Group News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:RAD) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.